Reprogramming of tumor-associated macrophages with anticancer therapies: Radiotherapy versus chemo- and immunotherapies

Géraldine Genard, Stéphane Lucas, Carine Michiels

Résultats de recherche: Contribution à un journal/une revueArticleRevue par des pairs

105 Téléchargements (Pure)

Résumé

Tumor-associated macrophages (TAMs) play a central role in tumor progression, metastasis, and recurrence after treatment. Macrophage plasticity and diversity allow their classification along a M1-M2 polarization axis. Tumor-associated macrophages usually display a M2-like phenotype, associated with pro-tumoral features whereas M1 macrophages exert antitumor functions. Targeting the reprogramming of TAMs toward M1-like macrophages would thus be an efficient way to promote tumor regression. This can be achieved through therapies including chemotherapy, immunotherapy, and radiotherapy (RT). In this review, we first describe how chemo- and immunotherapies can target TAMs and, second, we detail how RT modifies macrophage phenotype and present the molecular pathways that may be involved. The identification of irradiation dose inducing macrophage reprogramming and of the underlying mechanisms could lead to the design of novel therapeutic strategies and improve synergy in combined treatments.

langue originaleAnglais
Numéro d'article828
Nombre de pages19
journalFrontiers in Immunology
Volume8
Numéro de publicationJUL
Les DOIs
Etat de la publicationPublié - 2017

Empreinte digitale Examiner les sujets de recherche de « Reprogramming of tumor-associated macrophages with anticancer therapies: Radiotherapy versus chemo- and immunotherapies ». Ensemble, ils forment une empreinte digitale unique.

Contient cette citation